Back to Startup Insights
Bitterroot Bio
Cardio-immunology company developing immunomodulating therapies targeting CD47 to treat atherosclerotic cardiovascular disease (ASCVD), founded by CD47-discoverer Irving Weissman.
Headquarters
Palo Alto, USA / Needham, USA
Year Founded
2023
Founders
Irving Weissman (co-founder), ARCH Venture Partners
Country
United States
Financial Information
Funding Stage
Series A
Recent Funding
$145M
Funding By
ARCH Venture Partners, Deerfield Management, GV, Koch Disruptive Technologies
Core Technology
Anti-CD47 immunomodulation (BRB-002)
Product Type
Drug
Pipeline Stage (Very Important)
Phase IIa (MATADOR study)
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: FDA Clinical
- Clinical Trial Registration: MATADOR Phase 2a (ASCVD)
- Patents / IP Status: Filed
Partnerships
Pharma Collaborations
None disclosed
Academic / Hospital Tie-ups
Stanford University (Weissman lab)
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
First-in-class CD47 blockade to reverse atherosclerotic plaque